AstraZeneca (LON:AZN) Rating Kept
In analysts note issued to clients and investors on Tuesday, 6 February, Astrazeneca (LON:AZN) stock Mkt Perform was restate at Leerink Partners. They currently have a GBX 38.0 target price per share on the stock. Leerink Partners’s target price per share suggests a potential upside of 10.82 % from the company’s close price.
LON:AZN is at the moment trading -0.46% lower at GBX 4976.74 as of 5:06 PM London time. AstraZeneca’s stock is 0% over the last 200 days. It has underperformed the S&P500, which has surged 6.00% over the same time.
According to data compiled by Thomson Reuters, AstraZeneca (LON:AZN)’s stock is covered by 29 equity analysts across the Street, with 3 analysts giving it a Sell rating, 18 a Buy rating, while 13 consider it a Hold. The 12-month consensus target price for the stock is GBX 6196, which reflects an upside potential of 39.20% over the current price.
AstraZeneca (LON:AZN) Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
AstraZeneca (LON:AZN) traded down -0.46% on 6 February, hitting GBX 4976.74. A total of 1.04 million shares of the company’s stock traded hands. This is down from average of 2.13 million shares. AstraZeneca has a 52 week low of GBX 3996.00 and a 52 week high of GBX 5520. The company has a market cap of 63.08 billion GBX and a P/E ratio of 23.68.
Get the latest AstraZeneca (LON:AZN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Analysts at Leerink Partners Kept their Mkt Perform Rating for AstraZeneca (LON:AZN) with GBX 38.0 Target appeared first on Octafinance.